YM155 (Sepantronium Bromide)

For research use only.

Catalog No.S1130

111 publications

YM155 (Sepantronium Bromide) Chemical Structure

CAS No. 781661-94-7

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 447 In stock
USD 770 In stock
USD 1270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's YM155 (Sepantronium Bromide) has been cited by 111 publications

Purity & Quality Control

Choose Selective Survivin Inhibitors

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 M2HiSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rhdFczKGh? NHT1WFRFVVOR NVP0OIxoUUN3ME2wMlAxQSEEsTCwMlAxODlizszN Ml63NlU3PTl5M{G=
M-07e M1HHXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XOPVczKGh? MnLPSG1UVw>? NXjidHpXUUN3ME2wMlA1OCEEsTCwMlAyOyEQvF2= Moq1NlU3PTl5M{G=
THP-1 M3;0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[3NkBp NIHaU3FFVVOR Mo\kTWM2OD1yLkC1NUDDuSByLkCxN{DPxE1? MV[yOVY2QTd|MR?=
CMK NX;YbFlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYS3NkBp MV;EUXNQ NUHrc|FpUUN3ME2wMlA2OyEEsTCwMlAxQSEQvF2= MXKyOVY2QTd|MR?=
MV4-11 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\DZWM4OiCq NFHzV2tFVVOR NWf3NYdQUUN3ME2wMlA2PSEEsTCwMlAzQCEQvF2= MUGyOVY2QTd|MR?=
AML-193 M4LtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXO3NkBp MVLEUXNQ NEXWPIRKSzVyPUCuOFYzKMLzIECuNFYxKM7:TR?= MVWyOVY2QTd|MR?=
HL-60 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXvO|IhcA>? MoLSSG1UVw>? MnvhTWM2OD1yLkCwNUDDuSByLkCwNFIh|ryP MVKyOVY2QTd|MR?=
ML-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ewZVczKGh? MWrEUXNQ NW\sSI9OUUN3ME2wMlAxQSEEsTCwMlAxOiEQvF2= MnfrNlU3PTl5M{G=
OCI/AML3 MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnq4O|IhcA>? M2jWWWROW09? MoXJTWM2OD1yLkCxNUDDuSByLkCwNkDPxE1? M3LaW|I2PjV7N{Ox
HEL MkH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzidVB[PzJiaB?= NG\NZ|VFVVOR M{S5SGlEPTB;MD61OVkhyrFiMD6wN|gh|ryP NVPMc5drOjV4NUm3N|E>
ME-1 MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTK[VE4OiCq Mm\4SG1UVw>? NGDjR|JKSzVyPUCuOlg1KMLzIECuNVc6KM7:TR?= MkOzNlU3PTl5M{G=
THP-1 NH64TlNCeG:ydH;zbZMhSXO|YYm= MUmxxsDPxE1? NU\EbnM1PzJiaB?= M2DVbWROW09? NV\qR5JvcW6mdXPld{BieG:ydH;zbZM> M3K1RlI2PjV7N{Ox
M-07e NWTuNHJETnWwY4Tpc44hSXO|YYm= NVLNZ5ZzOOLCk{JCpO69VQ>? MUi3NkBp MYLEUXNQ M4LodIlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= NVGzdXBFOjV4NUm3N|E>
THP-1 NFHLb4tHfW6ldHnvckBCe3OjeR?= M{\KTFDjiJNzwrFOwG0> NVTQSnZbPzJiaB?= MnT3SG1UVw>? MULpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw MmX4NlU3PTl5M{G=
CMK M3Ll[WZ2dmO2aX;uJGF{e2G7 NUTlXJJkOOLCk{JCpO69VQ>? Ml7LO|IhcA>? MXTEUXNQ MVjpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw M2T4VFI2PjV7N{Ox
AML-193 NEHqfHpHfW6ldHnvckBCe3OjeR?= MoDsNQKBmzIEoN88US=> NWrFSGVbPzJiaB?= NUmxdotMTE2VTx?= NVX5[WlpcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> NYO1e|lUOjV4NUm3N|E>
Kasumi-1 MVrGeY5kfGmxbjDBd5NigQ>? MUew5qCUOcLizszN NIe1fXM4OiCq NWmyVY5QTE2VTx?= MlLXbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= NYLGSGRPOjV4NUm3N|E>
MV4-11 Ml3lSpVv[3Srb36gRZN{[Xl? Ml\HNQKBmzIEoN88US=> MX63NkBp MX;EUXNQ M1vZSYlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= M{HOTlI2PjV7N{Ox
MUG-Chor  MoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkCwNE02KM7:TR?= MmLVNlQwPDhiaB?= MnnVTWM2OD15LkC15qCKdk1iZn;yJFQ5cA>? MnHQNlU3PDBzOEW=
U-CH1  MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fudlAuPSEQvF2= NX3WbJVEOjRxNEigbC=> NGiyZ41KSzVyPUmuNFPjiImwTTDmc5IhPDiq M2jZcVI2PjRyMUi1
KATOIII NXrieWRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:xNE8zOCCwTR?= M4DXUVQ5KGh? NG\DVGFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{HVPFI2PjN3MEW1
AGS  M{jGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkmzNVAwOjBibl2= NEDtWHg1QCCq NYDwWIhncW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MonENlU3OzVyNUW=
SACC-83 NUOzXYVwTnWwY4Tpc44hSXO|YYm= MlLNOUBvVQ>? MV20PEBp M2nnfYRm[3KnYYPld{BvfWOuZXHyJIV5eHKnc4Ppc44hd2ZiSFnGMVHPuQ>? M17vdlI2PDh3NkO1
INA-6 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vVe|AuPTByIH7N Mom4OFghcA>? MUHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWiyOVI6Pjl5OB?=
U-266 MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWSwdI9ZOC13MECgcm0> M4DUSVQ5KGh? MVfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mlm4NlUzQTZ7N{i=
MOLP-8 MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXNVI9mOC13MECgcm0> MY[0PEBp MYXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NH22SYozPTJ7Nkm3PC=>
HG-1 M4TaNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCwMVUxOCCwTR?= NWH2Z45CPDhiaB?= M4G2d4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVXjU2hHOjV{OU[5O|g>
NCI-H929 NEf1NFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXWwMVUxOCCwTR?= MVO0PEBp NWDifIE5cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MlH2NlUzQTZ7N{i=
OPM-2 NUXzbm9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz0[Ig1OC13MECgcm0> MUe0PEBp M3PMXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{DSbVI2Ojl4OUe4
L-363 NV;PXndIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUewMVUxOCCwTR?= MlKyOFghcA>? NY\zeolbcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUTqW2pTOjV{OU[5O|g>
MOLP-2 M{LFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XaNVAuPTByIH7N M1\EVlQ5KGh? M4n3WIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MlT6NlUzQTZ7N{i=
KMS-12-BM NWPPRoFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnvcGUxNTVyMDDuUS=> MXq0PEBp NFjhVIVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUW5UVFTOjV{OU[5O|g>
SK-MM-2 NVHV[GNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TocVAuPTByIH7N Mn[5OFghcA>? MoD3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mof2NlUzQTZ7N{i=
U-266 MYLBdI9xfG:|aYOgRZN{[Xl? NULvZZd2OC13MDDuUS=> NVPxSYY2OjRiaB?= MUTpcoR2[2W|IHHwc5B1d3Orcx?= NVTlcoZPOjV{OU[5O|g>
INA-6  MYPBdI9xfG:|aYOgRZN{[Xl? M2f0TFAuPTBibl2= NHPBS5ozPCCq MkGxbY5lfWOnczDhdI9xfG:|aYO= M2T3TlI2Ojl4OUe4
MCF7 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfMfYF[PzJiaB?= MlHjTWM2OD1zMzFCtUA3KG6P Mk\ENlUzOjB{MkW=
MCF7-TamR6 NVTpVZl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLuO|IhcA>? NHzK[mdKSzVyPUigxtEhPiCwTR?= MoTnNlUzOjB{MkW=
MCF7-TamR7 NEC4fYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm3NkBp NELhW5JKSzVyPUigxtEhOyCwTR?= MVWyOVIzODJ{NR?=
MCF7-TamR8 NF2wd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYW3NkBp MkDuTWM2OD1zNTFCtUA3KG6P MofmNlUzOjB{MkW=
MCF7-TamC3 NIXDZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rFcVczKGh? M{HpR2lEPTB;NjFCtUA{KG6P M4rPelI2OjJyMkK1
MCF7-TamC6 MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDV[Yg4OiCq M3\sVmlEPTB;NjFCtUAxNjFibl2= NHr3OWIzPTJ{MEKyOS=>
MDA-MB-231 M{fkdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\r[GZrPzJiaB?= Mn;mTWM2OD13INMxJFEhdk1? MoSzNlUzOjB{MkW=
SK-BR-3 M1;6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXu3NkBp MVHJR|UxRTdiwsGgNE4{KG6P M1r2PFI2OjJyMkK1
Eca109 NGLVXJpHfW6ldHnvckBCe3OjeR?= Ml3qNU02OCCwTR?= Mn6xOFghcA>? NFzLcJlFVVOR M2XKfZN2eHC{ZYPz[ZMhe3W{dnn2bY4h\XiycnXzd4lwdiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MX6yOVE{QTN7NR?=
TE13 NH3WellHfW6ldHnvckBCe3OjeR?= NEPwOGwyNTVyIH7N MYe0PEBp M{mzRWROW09? MnfRd5VxeHKnc4Pld{B{fXK4aY\pckBmgHC{ZYPzbY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NGDtfZYzPTF|OUO5OS=>
Eca109 M4THOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkniNE0yODBibl2= M1LZfVI1NzR6IHi= NEK2WIpFVVOR MmTD[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4j6elI2OTN7M{m1
TE13 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFmwbpIxNTFyMDDuUS=> M2LhSlI1NzR6IHi= MWTEUXNQ NWq0VZNq\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYnnd21SOjVzM{mzPVU>
MT-3 MnPuT4lv[XOnIFHzd4F6 NIntVHU4OiCq NV:3OpFmTE2VTx?= MW\JR|UxRTJwOE[gxtEhOC53NDDuUUBnd3JiRGK0JIV5eHKnc4Ppc44> M1TXeFI1QDZ4NUi1
MDA-MB-468 Mmf0T4lv[XOnIFHzd4F6 NGjRUFc4OiCq NV3qWnZKTE2VTx?= NGm5T3JKSzVyPUCuNVEhyrFiMD6wNUBvVSCob4KgSHI1KGW6cILld5Nqd25? MXyyOFg3PjV6NR?=
SUM-159 MYLLbY5ie2ViQYPzZZk> MX:3NkBp MUTEUXNQ NUO2UZFFUUN3ME2xMlczKMLzIECuN|Mhdk1iZn;yJGRTPCCneIDy[ZN{cW:w M2fYbVI1QDZ4NUi1
MT-3 NW\kdpU3U2mwYYPlJGF{e2G7 NWr0SlhZPzJiaB?= Ml\ZSG1UVw>? MnX2TWM2OD13ND6xNUDDuSB2LkOyJI5OKG[xcjDEVlUh\XiycnXzd4lwdg>? M1e2PFI1QDZ4NUi1
MDA-MB-468 NVjzR2NCU2mwYYPlJGF{e2G7 NV7VRW1UPzJiaB?= M3TNN2ROW09? NVjZV5FFUUN3ME2wMlA4KMLzIECuNFIhdk1iZn;yJGRTPSCneIDy[ZN{cW:w MVSyOFg3PjV6NR?=
SUM-159 MlrjT4lv[XOnIFHzd4F6 Mn\WO|IhcA>? Mkf0SG1UVw>? MVzJR|UxRTZ7LkSgxtEhPC5{MzDuUUBnd3JiRGK1JIV5eHKnc4Ppc44> NXyxXm0yOjR6Nk[1PFU>
MT-3 + NAC M2XmTWtqdmG|ZTDBd5NigQ>? NG\pdnk4OiCq MoS4SG1UVw>? NHHscFRKSzVyPUW2MlIhyrFiMj6wO{BvVSCob4KgSHI2KGW6cILld5Nqd25? M1zrV|I1QDZ4NUi1
MT-3 + SB203580 MWrLbY5ie2ViQYPzZZk> NInWXlY4OiCq MUnEUXNQ NE\ySFRKSzVyPUO4MlQyKMLzIEWuNFIhdk1iZn;yJGRTPSCneIDy[ZN{cW:w NV;qbZNzOjR6Nk[1PFU>
DB NFvZfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[0UopiOTBibl2= M2jhVlI1KGh? NV;ZNHl3TE2VTx?= NWm2WG04cW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v M1rpb|I1PDh4NUm1
SU-DHL-8 M4HuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;tPFExKG6P MlPqNlQhcA>? NVjI[VU{TE2VTx?= NEn0RYxqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> MnW2NlQ1QDZ3OUW=
WSU-DLCL2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDEUWdSOTBibl2= M1LYVFI1KGh? M{DjeGROW09? MojtbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u NFHyW|QzPDR6NkW5OS=>
ACC-2 NV7QSnVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjqdVBTOC1zMECgcm0> NXXtOJNPOjRiaB?= MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MlPXNlQ{PzB7OUW=
ACC-2 NWHNSIF1SXCxcITvd4l{KEG|c3H5 M1PueFAuOjBibl2= NUTN[3lnOjRiaB?= M2HpXYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MkXLNlQ{PzB7OUW=
ACC-2 M4CzWGZ2dmO2aX;uJGF{e2G7 NEfkWnMxNTJyIH7N Mm\QNlQhcA>? MY\pcoNz\WG|ZYOgeIhmKGOxbo\ldpNqd25ib3[gUGM{USC2bzDMR|NKUQ>? NV7RWGhqOjR|N{C5PVU>
BFTC905 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTETHlIOC1zMECwJI5O NG\tbHU1QCCqwrC= MU\EUXNQ M3z1[mlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NELsZ2czPDJ7N{[0OC=>
T24 M1LSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULPNYlOOC1zMECwJI5O NGXnN5o1QCCqwrC= M3nNXWROW09? M3P1UmlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFHsUIkzPDJ7N{[0OC=>
TSGH8301  M1HSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrXeohNOC1zMECwJI5O M4HiPFQ5KGkEoB?= M{Pw[mROW09? MUTJR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnTENlQzQTd4NES=
BFTC909 M3nxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTtNE0yODByIH7N Ml3YOFghcMLi MliwSG1UVw>? MYXJR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYiyOFI6PzZ2NB?=
BFTC905 M4LlXmFxd3C2b4Ppd{BCe3OjeR?= NULXTWxUOjBibl2= MYK0PEBp M1SzdGROW09? MYrpcoR2[2W|IHHwc5B1d3Orcx?= MXeyOFI6PzZ2NB?=
BFTC905 MWTGeY5kfGmxbjDBd5NigQ>? NVflZXBmOjBibl2= MU[0PEBp M3u0dWROW09? M3vaTYRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzOELVnJ MVeyOFI6PzZ2NB?=
A2780p NEjibnBHfW6ldHnvckBCe3OjeR?= M1XsOFAuOTByIH7N MkLUNlQhcA>? MV3EUXNQ MUjpcoR2[2W|IGP1dpZqfmmwIHTve45z\We3bHH0bY9vyqB? NFnoOZYzPDJ4Mki3OS=>
A2780cis MYXGeY5kfGmxbjDBd5NigQ>? NF;2elYxNTFyMDDuUS=> MY[yOEBp M1\CXGROW09? M3nySYlv\HWlZYOgV5Vzfmm4aX6g[I94dnKnZ4XsZZRqd28EoB?= MUiyOFI3Ojh5NR?=
A2780p NGf6dm5CeG:ydH;zbZMhSXO|YYm= M2fQO|UuOTByIH7N MoWxNlQwPDhiaB?= M3H5XGROW09? M13jWIlv[3KnYYPld{BieG:ydH;zbZMhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> M3XtPFI1OjZ{OEe1
A2780cis Ml2zRZBweHSxc3nzJGF{e2G7 MmCxOU0yODBibl2= MUiyOE81QCCq MmPNSG1UVw>? NEnhR5pqdmO{ZXHz[ZMh[XCxcITvd4l{KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M4TFRVI1OjZ{OEe1
SH-SY5Y NXK5UI9zSXCxcITvd4l{KEG|c3H5 MXqxM|ExNzFyMDFCuW0> Ml3RO|IhcA>? MnqySG1UVw>? NF\zbWxqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NF24bJUzPDJ3NEW2NC=>
HL-60 M3[xdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXm3NuKhcA>? M2PET2ROW09? MmHiTWM2OD1yLkOgcm0> MUSyN|YyQDh4Mh?=
U937  MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G3UlczyqCq NFq0[XdFVVOR M4nEbWlEPTB;MD64JI5O M1XVUVI{PjF6OE[y
HL-60  NF71V4JHfW6ldHnvckBCe3OjeR?= MV:xxsDPxE1? MVu2M|EzNzJ2IHi= NXvzfY12TE2VTx?= NGDHdllqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kB{fXK4aY\pci=> MYKyN|YyQDh4Mh?=
U937  NGmzcpZHfW6ldHnvckBCe3OjeR?= M3POXFHDqM7:TR?= MnjDOk8yOi9{NDDo MkfRSG1UVw>? MXjpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDzeZJ3cX[rbh?= NV;hVXRPOjN4MUi4OlI>
HL-60 NF3WVnNCeG:ydH;zbZMhSXO|YYm= NVLqUZN4OC5zL{Gg{txO NX60VYtRQCCq M4[2PWROW09? Mkj2bY5lfWOnczDhdI9xfG:|aYO= NEHuVoQzOzZzOEi2Ni=>
Sk-NEP-1  MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf6NU0yODByMDDuUS=> NFO3VW4zPCCq NEnTeYxFVVOR M1\hSmlEPTB;MUCwJI5O NGLycYgzOzJ4N{[5PS=>
SK-NEP-1  M{jCT2Fxd3C2b4Ppd{BCe3OjeR?= MVS1NE8yODBibl2= M3rmclEzNzJ2IHi= MlnKSG1UVw>? NXTvbmpLcW6mdXPld{BieG:ydH;zbZM> NYP6WI5UOjN{Nke2PVk>
TC-32 NV[1TWFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLERZExNjFvMUCwNEBvVQ>? M4T2OmVEPTB;Mz6wJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NEDMZm4zOjl4MUe2Ny=>
TC-71 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvxNE4yNTFyMECgcm0> M{THfmVEPTB;NT63JI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{jaVlIzQTZzN{[z
SK-ES-1 NI\4cpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7qNE4yNTFyMECgcm0> Mlr6SWM2OD1{Lkigcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3O3SFIzQTZzN{[z
RD-ES MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXQN4FtOC5zLUGwNFAhdk1? M{f1OmVEPTB;Nj6yJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWOyNlk3OTd4Mx?=
HEK293 MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[wMlEuOTByMDDuUS=> NGLVd3pGSzVyPUKzMlAhdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MoS3NlI6PjF5NkO=
M059J M4L4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIO2V3AxNTVyIH7N MVG0PEBp MknYbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MoPaNlI4PzBzMUC=
M059K MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWwMVUxKG6P MXy0PEBp M3;FZYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{nGXlIzPzdyMUGw
M059J NV3HO5Z2SXCxcITvd4l{KEG|c3H5 MVKzNEBvVQ>? NGm0SIwzPCCq NIPUbmpqdmS3Y3XzJIFxd3C2b4Ppdy=> M4Kz[lIzPzdyMUGw
M059K NHvQVlBCeG:ydH;zbZMhSXO|YYm= MWKzNEBvVQ>? NELRbJkzPCCq MXvpcoR2[2W|IHHwc5B1d3Orcx?= NGniZmIzOjd5MEGxNC=>
PANC-1 NYnL[2dUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3yzc|AvODFvMUCwNEBvVQ>? M1ntSlQ5KGh? MV3JR|UxRTNwNkmgcm0> NVnpNoZWOjJ5MkO4O|E>
MIAPaCa-2 NWe2[oliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DhSFAvODFvMUCwNEBvVQ>? NWr6Om9MPDhiaB?= MUHJR|UxRTJ7LkO2JI5O M4r5clIzPzJ|OEex
BxPC-3 MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOwMlAyNTFyMECgcm0> M2qzSVQ5KGh? NVXkOGVjUUN3ME2zNE4zPiCwTR?= NXiyT5Z{OjJ5MkO4O|E>
PANC-1 NWjWTZY3TnWwY4Tpc44hSXO|YYm= MYGwMVExODBibl2= MkniNlQhcA>? NGjNXXpqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHhKSVBiYX7kJJN2en[rdnnuJIV5eHKnc4Ppc44> M3\QdlIzPzJ|OEex
MIAPaCa-2 M1TGOmZ2dmO2aX;uJGF{e2G7 MmLqNE0yODByIH7N M2fNR|I1KGh? M2\SZ4lv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gXGlCWCCjbnSgd5Vzfmm4aX6g[ZhxemW|c3nvci=> NVfhN|d2OjJ5MkO4O|E>
BxPC-3 M1uxSmZ2dmO2aX;uJGF{e2G7 M{DYXFAuOTByMDDuUS=> MWOyOEBp MXjpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGjJRXAh[W6mIIP1dpZqfmmwIHX4dJJme3Orb36= NWTvTlRNOjJ5MkO4O|E>
RPMI-7951 M4\G[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TNNWdKPTB;Mz6yJI5O M4DqSVIyPzN5NUCy
SK-MEL-5 NYXVOlJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFKyOVNIUTVyPUSuNkBvVQ>? NFmzUoUzOTd|N{WwNi=>
A375 NXnp[nZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjDO41IUTVyPU[uN{BvVQ>? NHvBc5gzOTd|N{WwNi=>
SK-MEL-28 NUe4V|B6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\IcFZIUTVyPUeuOkBvVQ>? MmnZNlE4Ozd3MEK=
SK-MEL-2 MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DQTWdKPTB;MUGgcm0> MoHkNlE4Ozd3MEK=
DB MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnURWk1QMLiaB?= MULHTVUxRTNwNTDuUS=> Mn\pNlEzOzd3MEi=
Pfeiffer MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLjOFjDqGh? NUfENFFKT0l3ME2zMlkhdk1? NXvwXGNmOjF{M{e1NFg>
SU-DHL-5 MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPmbIxJPDkEoHi= M3ewOmdKPTB;MD6yN{BvVQ>? M3rucVIyOjN5NUC4
SU-DHL-8 NF;iWYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LhflQ5yqCq MoS3S2k2OD1zLkSgcm0> MmmzNlEzOzd3MEi=
WSU-DLCL-2 NEn3OWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYW0POKhcA>? M3rqZWdKPTB;MT60JI5O NW\xVnFoOjF{M{e1NFg>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / XIAP / Caspase-7 / Caspase-9 / Caspase-3 / Cleaved Caspase-8 / PARP; 

PubMed: 26771139     


YM155 treatment decreased survivin expression without affecting XIAP and induced cleavage of caspases. Protein expression (caspase-3, -7, -9, -8, PARP) was detected by Western Blot analysis. 

β-catenin / c-Myc / Cyclin D1 / CD44 ; 

PubMed: 26771139     


YM155 inhibited expression of CSC molecules. SGC-7901 cells were treated with YM155 at indicated doses for 24 hours. The protein levels of genes were determined by Western Blot.

p-STAT3 / STAT3 ; 

PubMed: 22723871     


Levels of phosphorylated STAT3 and expression of survivin were analyzed by Western blotting after a 24-hours treatment with YM155 and 48 hours after transfection of 40 nM siRNA.

26771139 22723871
Immunofluorescence
EGFR; 

PubMed: 22723871     


YM155 (10 nM) induced the nuclear EGFR accumulation. PANC-1 cells were stained with anti-EGFR, anti-Alexa Fluor 488, and DAPI after the YM155 treatment. Scale bars: 10 µm.

PARP-1 / PAR ; 

PubMed: 26090615     


A. Nuclear accumulation of active PARP-1 in KYSE410 cells after 12 h of YM155 treatment was evaluated using immunofluorescent analysis. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. C. Accumulation of the poly-ADP polymer in KYSE410 was evaluated using immunofluorescent analysis after YM155 treatment for 12 h. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. 

22723871 26090615
Growth inhibition assay
Cell viability; 

PubMed: 29636860     


Cells were grown in 96-well plates for 24 h and treated with the indicated concentrations of YM155 or docetaxel for 72 h, and cell survival was determined by MTT assay.

29636860
In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol

Kinase Assay:

[1]

- Collapse

Promoter-luciferase reporter assay:

A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5
Cell Research:

[1]

- Collapse
  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
    (Only for Reference)

Solubility (25°C)

In vitro Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol '6 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage powder
in solvent
Synonyms N/A
Smiles CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Survivin Signaling Pathway Map

Related Survivin Products

Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID